The present invention relates to bispecific antibodies comprising a modified C-terminal crossfab fragment that have reduced or no reactivity against preexisting antidrug antibodies.

The disclosure provides multimeric proteins comprising three, four, or more monomer polypeptides, each comprising a first 4-1BB-targeting moiety, an oligomerization moiety, and optionally a linker. The monomer polypeptide may further comprise one or more additional targeting moieties. The oligomerization moiety promotes the trimerization, tetramerization, or higher state of oligomerization of the monomer polypeptides. Such multimeric proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators. The present disclosure also concerns methods of making the multimeric proteins described herein as well as compositions comprising such multimeric proteins. The present disclosure further relates to nucleic acid molecules encoding such multimeric proteins and methods for the generation of such multimeric proteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such multimeric proteins as well as compositions comprising one or more of such multimeric proteins.

Antibodies, including single-domain antibodies, that bind to SARS-CoV2 virus and methods of treatment using single-do-main antibodies that bind to SARS-CoV2 virus are provided.

The present describes monoclonal antibody to MUC1*.

The present invention relates to a low-molecular antibody composed of D-amino acids and achiral glycine, a method for producing the same, and a method for screening the low-molecular antibody using a mirror-image target protein corresponding to a target protein and an antibody library.

Disclosed herein are multi-specific antibody constructs that simultaneously bind two tumor cell surface antigens, GD2 and B7H3. The monovalent arms targeting GD2 and B7H3 are each low to moderate affinity for their respective antigens. The multi-specific antibodies disclosed herein bind to target tumor cells when both arms of the antibody bind to their antigens, resulting in high specificity of the antibody for GD2 and B7H3 expressing tumor cells.

The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.

Compositions and methods for selective targeting of BMP/TGF? signaling using heteromeric complexes, preferably comprising single chain variable domain (scFv) antibodies (Abs) targeting the extracellular domains of BMP type I and type II receptors.

The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.

The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brain. The present inventors found that the one-armed anti-human NR1 antibody according to the present invention binds to NR1 competitively with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody to thereby exhibit therapeutic effect on anti NMDAR encephalitis. Accordingly, the present invention provides the a one-armed anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition comprising the antibody, a use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti NMDAR encephalitis using the antibody.